13321 related articles for article (PubMed ID: 10338334)
21. Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins.
van Brussel JP; van Steenbrugge GJ; Romijn JC; Schröder FH; Mickisch GH
Eur J Cancer; 1999 Apr; 35(4):664-71. PubMed ID: 10492644
[TBL] [Abstract][Full Text] [Related]
22. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6.
Ishii M; Iwahana M; Mitsui I; Minami M; Imagawa S; Tohgo A; Ejima A
Anticancer Drugs; 2000 Jun; 11(5):353-62. PubMed ID: 10912951
[TBL] [Abstract][Full Text] [Related]
23. Characteristics of human gastric carcinoma cell lines with induced multidrug resistance.
Kang MS; Kim HS; Han JA; Park SC; Kim WB; Park JG
Anticancer Res; 1997; 17(5A):3531-6. PubMed ID: 9413198
[TBL] [Abstract][Full Text] [Related]
24. [Multidrug resistance].
Mickisch GH
Urologe A; 1996 Sep; 35(5):370-7. PubMed ID: 8915096
[TBL] [Abstract][Full Text] [Related]
25. Increased phosphorylation of DNA topoisomerase II in etoposide resistant mutants of human glioma cell line.
Matsumoto Y; Kunishio K; Nagao S
J Neurooncol; 1999; 45(1):37-46. PubMed ID: 10728908
[TBL] [Abstract][Full Text] [Related]
26. Role of oncogenes in resistance and killing by cancer therapeutic agents.
el-Deiry WS
Curr Opin Oncol; 1997 Jan; 9(1):79-87. PubMed ID: 9090498
[TBL] [Abstract][Full Text] [Related]
27. Spontaneous overexpression of the long form of the Bcl-X protein in a highly resistant P388 leukaemia.
Kühl JS; Krajewski S; Durán GE; Reed JC; Sikic BI
Br J Cancer; 1997; 75(2):268-74. PubMed ID: 9010037
[TBL] [Abstract][Full Text] [Related]
28. Establishment and characterization of renal cell carcinoma cell lines with multidrug resistance.
Yu DS; Ma CP; Chang SY
Urol Res; 2000 Apr; 28(2):86-92. PubMed ID: 10850629
[TBL] [Abstract][Full Text] [Related]
29. Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells.
Eijdems EW; Zaman GJ; de Haas M; Versantvoort CH; Flens MJ; Scheper RJ; Kamst E; Borst P; Baas F
Br J Cancer; 1995 Aug; 72(2):298-306. PubMed ID: 7640209
[TBL] [Abstract][Full Text] [Related]
30. [Multidrug resistance mechanisms in cell line HL-60/VCR].
Zhu XH; Li JY; Xia XM; Zhu MQ; Geng MJ; Chen L; Zhang JQ
Ai Zheng; 2002 Dec; 21(12):1310-3. PubMed ID: 12520737
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic.
Liu J; Chen H; Miller DS; Saavedra JE; Keefer LK; Johnson DR; Klaassen CD; Waalkes MP
Mol Pharmacol; 2001 Aug; 60(2):302-9. PubMed ID: 11455017
[TBL] [Abstract][Full Text] [Related]
32. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
Pérez-Tomás R
Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198
[TBL] [Abstract][Full Text] [Related]
33. Multidrug resistance-associated protein: a protein distinct from P-glycoprotein involved in cytotoxic drug expulsion.
Barrand MA; Bagrij T; Neo SY
Gen Pharmacol; 1997 May; 28(5):639-45. PubMed ID: 9184795
[TBL] [Abstract][Full Text] [Related]
34. Effect of phosphatase and tensin homology deleted on chromosome 10 (PTEN) gene transfection on reversal of multidrug resistance in K562/ADM cells.
Cheng Z; Yang N; Liang W; Yan X; Li L; Pan L
Leuk Lymphoma; 2012 Jul; 53(7):1383-9. PubMed ID: 22185283
[TBL] [Abstract][Full Text] [Related]
35. Emergence of different mechanisms of resistance in the evolution of multidrug resistance in murine erythroleukemia cell lines.
Modrak DE; Draper MP; Levy SB
Biochem Pharmacol; 1997 Dec; 54(12):1297-306. PubMed ID: 9393672
[TBL] [Abstract][Full Text] [Related]
36. Effects of 1,2-naphthoquinones on human tumor cell growth and lack of cross-resistance with other anticancer agents.
Dolan ME; Frydman B; Thompson CB; Diamond AM; Garbiras BJ; Safa AR; Beck WT; Marton LJ
Anticancer Drugs; 1998 Jun; 9(5):437-48. PubMed ID: 9660542
[TBL] [Abstract][Full Text] [Related]
37. Characterization of chemoresistance mechanisms in a series of cisplatin-resistant transitional carcinoma cell lines.
Hour TC; Chen J; Huang CY; Guan JY; Lu SH; Hsieh CY; Pu YS
Anticancer Res; 2000; 20(5A):3221-5. PubMed ID: 11062746
[TBL] [Abstract][Full Text] [Related]
38. P-glycoprotein expression in primary and metastatic malignant melanoma.
Schadendorf D; Herfordt R; Czarnetzki BM
Br J Dermatol; 1995 Apr; 132(4):551-5. PubMed ID: 7748745
[TBL] [Abstract][Full Text] [Related]
39. Expression patterns of multidrug-resistance (MDR1), multidrug resistance-associated protein (MRP),glutathione-S-transferase-pi (GST-pi) and DNA topoisomerase II (Topo II) genes in renal cell carcinomas and normal kidney.
Kim WJ; Kakehi Y; Kinoshita H; Arao S; Fukumoto M; Yoshida O
J Urol; 1996 Aug; 156(2 Pt 1):506-11. PubMed ID: 8683726
[TBL] [Abstract][Full Text] [Related]
40. ROR2 increases the chemoresistance of melanoma by regulating p53 and Bcl2-family proteins via ERK hyperactivation.
Castro MV; Barbero GA; Máscolo P; Ramos R; Quezada MJ; Lopez-Bergami P
Cell Mol Biol Lett; 2022 Mar; 27(1):23. PubMed ID: 35260073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
